학술논문
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Document Type
Article
Author
Mauro, M.J.; Geyer, M.B.; Hughes, T.P.; Kim, D.-W.; Rea, D.; Cortes, J.E.; Hochhaus, A.; Sasaki, K.; Breccia, M.; Talpaz, M.; Ottmann, O.; Minami, H.; Goh, Y.T.; DeAngelo, D.J.; Heinrich, M.C.; Gómez-García de Soria, V.; le Coutre, P.; Mahon, F.-X.; Janssen, J.J.W.M.; Deininger, M.; Shanmuganathan, N.; Cacciatore, S.; Polydoros, F.; Agrawal, N.; Hoch, M.; Lang, F.
Source
In: Leukemia . (Leukemia, May 2023, 37(5):1048-1059)
Subject
Language
English
ISSN
14765551
08876924
08876924